hepatitis C

Gilead Sciences, Inc Not Likely To Go For Large M&A: Maxim Group
Bidness, ETC
Tue, 11/3/15 - 09:14 am
Gilead Sciences
M&A
Japan
hepatitis C
Express Scripts to maintain availability of AbbVie's hep C drug
Yahoo/Reuters
Wed, 10/28/15 - 02:58 pm
Express Scripts
AbbVie
hepatitis C
Viekira Pak
Merck says it won't need AbbVie-sized discounts to win in hep C
Fierce Pharma Marketing
Wed, 10/28/15 - 09:56 am
Merck
AbbVie
hepatitis C
If It Happened To AbbVie, Could It Also Happen To Gilead?
Seeking Alpha
Mon, 10/26/15 - 09:40 pm
AbbVie
Gilead Sciences
hepatitis C
Gilead: A Winner On 3 Fronts
Seeking Alpha
Sun, 10/25/15 - 06:28 pm
Gilead Sciences
AbbVie
hepatitis C
FDA's Warning Shakes Up Hep C Landscape
Investopedia
Fri, 10/23/15 - 05:08 pm
FDA
warnings
hepatitis C
AbbVie
Gilead Sciences
Harvoni
Viekira Pak
How FDA Warning Could Spell Disaster for AbbVie and Opportunity for Gilead
24/7 Wall St
Fri, 10/23/15 - 11:08 am
FDA
Gilead Sciences
AbbVie
hepatitis C
warnings
Viekira Pak
Technivie
FDA issues warning on AbbVie hep C drugs and drugmaker's shares fall 10%
Fierce Pharma
Thu, 10/22/15 - 07:30 pm
FDA
hepatitis C
AbbVie
liver damage
Technivie
Viekira Pak
Merck HCV Treatment: The Next Big Breakthrough?
Bidness, ETC
Wed, 10/21/15 - 10:31 am
Merck
hepatitis C
elbasvir/grazoprevir
MK-36822
MK-84083
Medicare covered $4.6B in hep C scripts for H1, and Gilead's the big winner
Fierce Biotech
Tue, 10/20/15 - 06:07 pm
Medicare
hepatitis C
Gilead Sciences
Johnson & Johnson Tells Gilead Sciences "Game On"
Motley Fool
Tue, 10/20/15 - 10:08 am
JNJ
Gilead Sciences
hepatitis C
Olysio
Incivek
Harvoni
Sovaldi
Buy Gilead: Hep-C Market Is At Least $500 Billion Over The Next 10 Years
Seeking Alpha
Thu, 10/15/15 - 03:50 pm
hepatitis C
Gilead Sciences
Gilead Sciences Latest HCV Scripts Spell Trouble; Will The Trend Last?
Bidness, ETC
Mon, 10/12/15 - 09:13 am
Gilead Sciences
Sovaldi
Harvoni
hepatitis C
2 Reasons Gilead Sciences Suffered Through a Rough September
Motley Fool
Sun, 10/11/15 - 01:48 pm
Gilead Sciences
drug pricing
Harvoni
Sovaldi
hepatitis C
Can Daklinza profit from a set of niche hep C uses? BMS may soon find out
Fierce Pharma Marketing
Wed, 10/7/15 - 10:00 am
Daklinza
Bristol-Myers Squibb
hepatitis C
Is Gilead Sciences' Dominance in Hepatitis C Unstoppable?
Motley Fool
Tue, 09/29/15 - 09:04 am
Gilead Sciences
hepatitis C
Harvoni
Sovaldi
AbbVie
Viekira Pak
Achillion
Enanta, among Boston's few profitable biotechs, earns another $30M
Bizjournals.com
Mon, 09/28/15 - 08:41 am
Enanta
AbbVie
hepatitis C
Viekirax
Here are the 5 drug classes with the biggest price gains
Fortune
Wed, 09/23/15 - 10:02 pm
hepatitis C
compounded drugs
diabetes
hemophilia
painkillers
After Harvoni: A pangenotype hep C combo could be Gilead's next breakthrough
BioPharma Dive
Tue, 09/22/15 - 11:45 am
Gilead Sciences
Harvoni
hepatitis C
Sovaldi
Gilead combo drug fights all forms of hep C infection: data
Yahoo/Reuters
Mon, 09/21/15 - 10:51 am
Gilead
hepatitis C
velpatasvir
Sovaldi

Pages